| Identification | Back Directory | [Name]
5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide monohydrate | [CAS]
73360-56-2 | [Synonyms]
Cestocide
Zestocarp
2',5-D733ichloro-4'-nitrosalicylanilide Hydrate
N-(2-Chloro-4-nitrophenyl)-5-chlorosalicylaMide Hydrate
5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzaMide Hydrate
5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide monohydrate | [Molecular Formula]
C13H8Cl2N2O4.H2O | [MDL Number]
MFCD16620468 | [MOL File]
73360-56-2.mol | [Molecular Weight]
345.14 |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS09 | [Signal word ]
Warning | [Hazard statements ]
H400 | [Precautionary statements ]
P273 | [Hazard Codes ]
N | [Risk Statements ]
50 | [Safety Statements ]
61 | [RIDADR ]
UN 3077 9 / PGIII | [WGK Germany ]
2 | [RTECS ]
VN8400000 |
| Hazard Information | Back Directory | [Uses]
5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide monohydrate is used as an anthelmintic drug (Cestodes).
| [in vivo]
Niclosamide monohydrate (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3]. | Animal Model: | Nu+/Nu+ mice injected with NCI-H295R cells[3] | | Dosage: | 100 mg/kg, 200 mg/kg | | Administration: | Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks | | Result: | Showed a 60%-80% inhibition in tumor growth, as compared to the control group. |
| [IC 50]
STAT3: 0.25 μM (IC50, in HeLa cells) |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|